Identificador para citar o enlazar este ítem: http://hdl.handle.net/20.500.13003/13588
Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study
Identificadores
ISSN: 0211-6995
eISSN: 1989-2284
WOS ID: 000330912000008
Scopus EID: 2-s2.0-84894600738
PMID: 24463864
Embase PUI: L605668270
Compartir
Estadísticas
Ver estadísticas de uso de este ítemMetadatos
Ver el registro Dublin Core del ítemAutor
Torregrosa, Josep V.; Morales, Enrique; Diaz, Juan M.; Crespo, Josep; Bravo, Juan; Gomez-Marquez, Gonzalo; Gentil, Miguel A.; Rodriguez-Benot, Alberto; Rodriguez-Garcia, Minerva; Lopez-Jimenez, Veronica; Gutierrez-Dalmau, Alex; Jimeno, Luisa; Jose Perez-Saez, M.; Romero, Rafael; Gomez-Alamillo, Carlos; Grp Estudio CINARENFecha de publicación
2014Tipo de documento
research articleCitación
Torregrosa JV, Morales E, Diaz JM, Crespo J, Bravo J, Gomez G, et al. Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study. Nefrologia. 2014;34(1):62-8.Resumen
Background: The effect of cinacalcet in patients with persistent secondary hyperparathyroidism (SHPT) after kidney transplantation (KT) has mainly been reported in patients with secondary hypercalcaemia. Objectives: Our objective was to assess the long-term effect of cinacalcet on patients with a KT and normocalcaemic SHPT. Methods: A one-year multicentre, observational, retrospective study that included kidney recipients with SHPT (intact parathyroid hormone [iPTH] > 120pg/ml) and calcium levels within the normal range (8.4-10.2mg/dl). Patients began treatment with cinacalcet in clinical practice. Results: 32 patients with a mean age (standard deviation [SD] of 54 (11) years, 56% male, were included in the study. Treatment with cinacalcet began a median of 16 months after KT (median dose of 30mg/day). Levels of iPTH decreased from a median (P25, P75) of 364 (220, 531) pg/ml at the start of the study to 187 (98, 320) after 6 months (48.6% reduction, P=.001) and to 145 (91, 195) after 12 months (60.2% reduction, P=.001), without there being changes in calcium and phosphorus levels (P=.214 and P=.216, respectively). No changes were observed in kidney function or anti-calcineuric drug levels. 3.1% of patients discontinued cinacalcet due to intolerance and 6.2% due to a lack of efficacy. Conclusions: In patients with normocalcaemic SHPT after KT cinacalcet improves the control of serum PTH values without causing changes to calcaemia, phosphataemia or kidney function. Cinacalcet showed good tolerability.
Versión del editor
https://dx.doi.org/10.3265/Nefrologia.pre2013.Aug.12183Palabras clave
CinacalcetSecondary hyperparathyroidism
Kidney transplantation
Parathyroid hormone
Calcium
Phosphorus
MeSH
Kidney TransplantationMale
Time Factors
Female
Follow-Up Studies
Humans
Naphthalenes
Postoperative Complications
Hyperparathyroidism, Secondary
Middle Aged
Retrospective Studies
DeCS
Estudios de SeguimientoNaftalenos
Complicaciones Posoperatorias
Hiperparatiroidismo Secundario
Humanos
Persona de Mediana Edad
Factores de Tiempo
Femenino
Trasplante de Riñón
Estudios Retrospectivos
Masculino